New and Promising Chemotherapeutics for Emerging Infections Involving Drug-Resistant Non-albicans Candida Species.

New and Promising Chemotherapeutics for Emerging Infections Involving Drug-Resistant Non-albicans Candida Species. Curr Top Med Chem. 2019 Oct 25;: Authors: Silva LN, de Mello TP, de Souza Ramos L, Branquinha MH, Dos Santos ALS Abstract Fungal infections are a veritable public health problem worldwide. The increasing number of patient populations at risk (e.g. transplanted individuals, cancer patients and HIV-infected people) as well as the use of antifungal agents for prophylaxis in medicine have favored the emergence of previously rare or newly identified fungal species. Indeed, novel antifungal resistance patterns have been observed, including environmental sources and the emergence of simultaneous resistance to different antifungal classes, especially in Candida spp., which are known for the multidrug-resistance (MDR) profile. In order to circumvent this alarming scenario, the international researchers' community is engaged on discovering new, potent and promising compounds to be used in a near future to treat resistant fungal infections in hospital settings in a global scale. In this context, many compounds with antifungal action from both natural and synthetic sources are currently under clinical development, including those that target either ergosterol or β(1,3)-D-glucan, presenting clear evidences of pharmacologic/pharmacokinetic advantages over currently available drugs against these two well-known fungal target structures...
Source: Topics in HIV Medicine - Category: Infectious Diseases Authors: Tags: Curr Top Med Chem Source Type: research